… colchicine-resistant FMF patients and has an acceptable safety profile [23–34]. On the other
hand, data concerning efficacy … compare anakinra and canakinumab regarding efficacy and …

… Indeed, in an analysis of long-term data from the CLUSTER study of canakinumab in
patients with FMF, 96.7% of these colchicine resistant patients had an exon 10 variant and 70% …

… colchicine-resistant FMF (crFMF) patients (6-10). There are 3 anti-IL-1 agents available:
anakinra… cessful management of colchicine resistant familial Mediterranean fever patients with a …

… Conclusions: This is the largest cohort of adolescent FMF patients with menstruation-… A
management algorithm for familial Mediterranean fever (FMF) patients with menstruation…

… treatment in patients with colchicine-resistant FMF. However, … studies have shown that
anakinra and canakinumab may be … trial has confirmed the efficacy and safety of canakinumab in …

… The efficacy and safety of canakinumab on colchicine-resistant patients is less known …
colchicine resistant. Patients with persistent arthritis were treated with methotrexate and etanercept …

… Familial Mediterranean Fever (FMF) is the most common … and/or canakinumab Patients were
started Anakinra only when … To the best of our knowledge, this study provides efficacy and …

… defined an adolescent, with recurrent fever and abdominal … A RCT, which included 24
colchicine-resistant FMF (crFMF) … ), with a good safety profile on the anakinra arm [154]. Recently …

… To study current knowledge on anakinra treatment for FMF, … “familial Mediterranean fever”
crossed with the term “anakinra” … efficacy and safety of canakinumab for colchicine resistant …

… Recurrent self-limited attacks of fever and short-lived inflammation in the serosal membranes,
joints, and skin are the leading features of familial Mediterranean fever (FMF), the most …